These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6404852)

  • 1. Endemic resistance to amikacin among hospital isolates of gram-negative bacilli: implications for therapy.
    Wormser GP; Tatz J; Donath J
    Infect Control; 1983; 4(2):93-9. PubMed ID: 6404852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
    Moellering RC; Wennersten C; Kunz LJ; Poitras JW
    Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
    Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F
    J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term amikacin use. Effects on aminoglycoside susceptibility patterns of gram-negative bacilli.
    Moody MM; de Jongh CA; Schimpff SC; Tillman GL
    JAMA; 1982 Sep; 248(10):1199-202. PubMed ID: 6809965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the in vitro activities of BB-K8 and three other aminoglycosides against 215 strains of Pseudomonas and Enterobacteriaceae with variable sensitivity to kanamycin and gentamicin.
    Yourassowsky E; Schoutens E; Vanderlinden MP
    Chemotherapy; 1975; 21(1):45-51. PubMed ID: 807457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF; Maslow MJ; Leibowitz RE; Pollock AA; Hanna BA; Schaefler S; Simberkoff MS; Rahal JJ
    J Infect Dis; 1985 Feb; 151(2):295-300. PubMed ID: 3918124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA; Farrell W; Maskell J; Williams JD
    Br Med J; 1976 Nov; 2(6047):1284-7. PubMed ID: 1000196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin.
    Knothe H
    J Infect Dis; 1976 Nov; 134 SUPPL():S271-4. PubMed ID: 825585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
    Reyonolds AV; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
    Reynaud AE; Coude du Foresto B; Derriennic M; Courtieu AL
    Pathol Biol (Paris); 1988 May; 36(5):435-8. PubMed ID: 3136424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus.
    Díez Enciso M; Mateos Lindemann M; Gutiérrez Altés A
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1064-6. PubMed ID: 6818899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].
    Schassan HH
    Infection; 1976; 4(2):35-41. PubMed ID: 789246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endemic aminoglycoside resistance in gram-negative bacilli: epidemiology and mechanisms.
    Weinstein RA; Nathan C; Gruensfelder R; Kabins SA
    J Infect Dis; 1980 Mar; 141(3):338-45. PubMed ID: 6767795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibacterial activity of amikacin towards gentamicin-resistant, Gram-negative bacilli].
    Nicoletti G; Russo G; Toscano MA; Gismondo MR
    Boll Ist Sieroter Milan; 1979 Jan; 57(6):713-7. PubMed ID: 121911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of netilmicin, gentamicin, tobramycin and amikacin against glucose fermenting and nonfermenting bacteria.
    DiPersio JR; Krafczyk TL
    Chemotherapy; 1980; 26(5):323-33. PubMed ID: 7389428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.
    Gerding DN; Larson TA
    Am J Med; 1986 Jun; 80(6B):22-8. PubMed ID: 3089003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.